Author's response to reviews

Title: Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients

Authors:

Gunjan Srivastava (gsrivastava123@gmail.com)
Jasmeet Assi (jasmeet.assi@gmail.com)
Lawrence Kashat (lkashat@gmail.com)
Ajay Matta (matta.ajay@gmail.com)
Martin Chang (MChang2@mtsinai.on.ca)
Paul G Walfish (pwalfish@mtsinai.on.ca)
Ranju Ralhan (rralhan@mtsinai.on.ca)

Version: 4 Date: 27 August 2014

Author's response to reviews: see over
Dated: August 27, 2014.

Dr. Emily Crow

Editor, BMC Cancer

Biomed Central Editorial office

Subject: MS: 2019472866127276 - Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.

Authors: Gunjan Srivastava, Jasmeet Assi, Lawrence Kashat, Ajay Matta, Martin Chang, Paul G Walfish and Ranju Ralhan

Dear Dr. Crow,

Please find below the pointwise response to Reviewer’s comments.

Reviewer’s comment: Consent: Please revise your manuscript to clearly state whether the patients whose records were used for this study granted informed consent for their tissue samples to be archived and used for research purposes.

Authors’ response:

This retrospective study of biomarkers using the breast cancer patients’ tissue blocks stored in the archives of the Department of Pathology and Laboratory Medicine and their anonymized clinical data was approved by the Mount Sinai Hospital Research Ethics Board, Toronto, Canada. The patients whose records were used for this study granted informed consent for their tissue samples to be archived and used for research purposes. In view of the retrospective study, the need for consent for use of anonymized clinical data was waived-off by the Institutional Research Ethics Board.

(See line 4 on page 9)

Looking forward to a favorable response.

Thanks.

Ranju Ralhan